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Summary
Objective: To investigate the effect of glucosamine (GlcN) in a human osteoarthritic explant model on expression of genes involved in anabolic
and catabolic activities of chondrocytes.
Methods: Human osteoarthritic explants, obtained during knee arthroplasty surgery, were pre-cultured (3 days) and treated with glucosamine-
hydrochloride (GlcN-HCl) or glucosamine-3-sulphate (GlcN-S) at 0.5 mM and 5 mM (4 days). RNA was isolated from the explants and real
time RT-PCR was performed. Additionally, total matrix metalloproteinase (MMP) activity was measured in culture medium.
Results: Addition of 5 mM GlcN led to signiﬁcant down-regulation of aggrecan (2.65e7.73-fold) and collagen type II (7.75e22.17-fold) gene
expression, indicating inhibited anabolic activity. Considering catabolic activities, 5 mM GlcN signiﬁcantly down-regulated aggrecanase-1 and
MMP3 and 5 mM GlcN-S additionally down-regulated aggrecanase-2 and tissue inhibitor of MMP gene expression signiﬁcantly. Gene expres-
sion was not signiﬁcantly altered by 0.5 mM GlcN. Total MMP activity in culture medium was only signiﬁcantly reduced after addition of 5 mM
GlcN-HCl.
Conclusion: The effects of GlcN on gene expression in a human osteoarthritic explant model suggest that enzymatic breakdown of the extra-
cellular matrix might be reduced by the addition of 5 mM GlcN. Additionally, restoration of already damaged cartilage is not to be expected,
because gene expression of anabolic genes is also down-regulated. We suggest that chondroprotective properties of GlcN in vivo may be
based on inhibiting further degradation due to catabolic activities, rather than on the ability to rebuild cartilage.
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SocietyIntroduction
Glucosamine (GlcN) is becoming increasingly popular as an
alternative treatment for osteoarthritis (OA). There is evi-
dence in the literature that GlcN is equally effective or
even better in decreasing pain in patients with knee OA,
as compared to low dose Non-Steroidal Anti-Inﬂammatory
Drug (NSAID) use1,2. Furthermore, two publications
showed less joint space narrowing in people with knee
OA who took GlcN compared to placebo, over a period of
3 years3,4. Both articles conclude that GlcN could delay
the progression of knee OA. The authors speculate that
GlcN might have an effect on the chondrocytes due to stim-
ulation of anabolic activities and depression of catabolic
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Received 6 June 2005; revision accepted 4 October 2005.25activities. Some in vitro studies indeed showed a positive
effect of GlcN on glycosaminoglycan (GAG) production in
human chondrocyte cell cultures and the same anabolic ef-
fect was found on bovineand rat explants5e9. Controversially,
others found no effect or even an inhibition on GAG produc-
tion following GlcN addition10e16. Inconsistent results were
also found for the effect of GlcN on catabolic activities. These
in vitro studies used interleukin-1 (IL-1), lipopolysaccharide
or retinoic acid tomimic adegenerativeenvironment for chon-
drocytes in culture and thereby induce the synthesis of cata-
bolic factors such as matrix metalloproteinase (MMP) and
aggrecanase. Considering the ﬁnal result of catabolic activi-
ties, i.e., degradation of GAG, studies using IL-1 as a model
for degeneration found that GlcN decreased GAG degrada-
tion in some cases, but in other cases no such effect was
found6,11,12,17,18. In the studies using lipopolysaccharide or
retinoic acid as a model for degeneration, treatment with
GlcN consistently led to a decreased GAG degradation in
all cases12,14,17,19e21. Since GAG degradation ﬁnally is the
result of enzymatic breakdown, several studies investigated
the effects of GlcN on extra-cellular matrix degrading
enzymes in a culture system using IL-1, lipopolysaccharide
or retinoic acid. Most of these studies found that addition of0
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vity6,11,16,18,20,22. One study observed no effect on MMP
activity and another study found no changes in aggrecanase
activity after GlcN addition14,21.
The majority of the in vitro studies testing GlcN have been
performed with chondrocytes from different animal species
(bovine, equine, rat, dog and mouse chondrocytes). We
found only eight studies in the literature that used human
chondrocytes and none of these studies used the physio-
logically relevant human osteoarthritic cartilage explant cul-
ture system5e7,10,23e27.
The aim of our study was to investigate the expression of
genes, involved in both anabolic and catabolic activities of
chondrocytes, in response to GlcN treatment in a human
OA explant model. In addition to gene expression screening
we also studied whether changes in the transcription led to
altered overall enzymatic activity as well.
Materials and methods
EXPLANT PREPARATION
Human osteoarthritic cartilage was obtained during total
knee replacement surgery (12 patients; age 51e79 years,
Kellgren and Lawrence grade 2.9 0.67 (mean SD)).
Pre-operative treatment regimes were not considered. For
each patient, the experimental condition was compared to
the control condition. Explants were taken from areas of
macroscopically normal cartilage (with knowledge that this
cartilage is affected by the disease process) from both the
femoral condyles and the tibial plateau using a 4 mm diam-
eter dermal biopsy punch, and freed from the underlying
bone by dissection with a scalpel. After dissection, the ex-
plants were all pooled in a Petri dish. For each condition,
six explants were randomly taken from the Petri dish and cul-
tured in a six-well plate with 3 ml low glucose (1000 mg/l,
5.55 mM) Dulbecco’s Modiﬁed Eagle Medium (DMEM;
Gibco, Grand Island, NY), supplemented with 10%
foetal calf serum (FCS), 50 mg/ml gentamicin, 1.5 mg/ml
fungizone and freshly added 25 mg/ml L-ascorbic acid-2-
phosphate. The amount of glucose present in the FCS
added was less than 0.5 mM and is neglected. We only
started an explant culture when the amount of cartilage
was enough to make at least 12 explants and we were
thus able to culture experimental and one control conditions.
CULTURE EXPERIMENTS
After an initial 3-day pre-culture period (days 0e3), exper-
imental reagents were added for 4 days (days 3e7). For the
experimental conditions, culture medium (see above) was
supplemented with 0.5 mM and 5 mM glucosamine-hydro-
chloride (GlcN-HCl; Sigma, St Louis, MO) or glucosamine-
3-sulphate (GlcN-S; Sigma, St Louis, MO). As a control,
culture medium and culture medium supplemented with
5 mM glucose (Gluc; Sigma, St Louis, MO; ﬁnal Gluc con-
centration 10.5 mM) were used. Culture medium with or
without supplements was refreshed once. Conditioned
medium from all time points of refreshment and when the
explants were harvested was stored at 20(C for analysis.
Explants were harvested after a total of 7 days of culture.
GENE EXPRESSION ANALYSIS
At harvesting, six explants were collected and snap fro-
zen in liquid nitrogen. The wet weight per sample was deter-
mined and the frozen cartilage was then processed using
the Mikro-Dismembrator S (B. Braun Biotech InternationalGmbH, Melsungen, Germany). RNA was extracted using
RNA-Bee (TEL-TEST, Inc; Friendswood, TX, USA) ac-
cording to manufacturer’s guidelines and subsequently pre-
cipitated with 2-propanol. RNA was further puriﬁed using
RNeasy Micro Kit (Qiagen, Venlo, The Netherlands) with
on-column DNA-digestion. Total RNA was quantiﬁed accu-
rately using Ribogreen reagent (R-11490, Molecular
Probes Europe BV, Leiden, The Netherlands) according
to manufacturer’s instructions and 500 ng total RNA of
each sample was reverse transcribed into complementary
DNA (cDNA) using RevertAid First Strand cDNA Synthe-
sis Kit (MBI Fermentas, Germany). Primers and probe
sets were designed using PrimerExpress 2.0 software (Ap-
plied Biosystems, Foster City, CA, USA) to meet TaqMan
requirements and were designed to bind to separate exons
to avoid false positive results arising from ampliﬁcation of
contaminating genomic DNA. BLASTN search was used
to ensure gene speciﬁcity of all oligo-nucleotide sequences.
The primer and probe nucleotide sequences can be found
in Table I. Collagen II (COL2) and Glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH) assays were adopted from
Martin et al.28. Both anabolic genes (encoding for extra-cel-
lular matrix components) and catabolic genes (involved in
degradation of the extra-cellular matrix) were studied. Taq-
Man assays were performed on an ABI 7700 as described
earlier and data are presented as relative expression nor-
malized to GAPDH (2DDCt) according to Mandl et al.29
and Livak and Schmittgen30.
TOTAL MMP ASSAY
The stored culture mediumwas used to determine general
MMP activity as described earlier31. General MMP activity
was measured using 5 mM (all concentrations are ﬁnal)
ﬂuorogenic substrate TNO211-F (Dabcyl-Gaba-Pro-Gln-
Gly-Leu-Cys[Fluorescein]-Ala-Lys-NH2) in the presence or
absence of 12.5 mM BB94 (a general MMP inhibitor).
Medium samples were diluted (ﬁnal dilution 1/2) in MMP
buffer (50 mM Tris [pH 7.5], 5 mM CaCl2, 150 mM NaCl,
1 mMZnCl2, 0.01% Brij-35, 0.02%NaN3) containing the gen-
eral proteinase inhibitor (Complete, EDTA-free, one tablet in
10 ml). The MMP activity in each sample was calculated as
the difference in the initial rate of substrate conversion
(linear increase in ﬂuorescence in time, expressed as rela-
tive ﬂuorescence units per second) between samples with
and without BB94 addition. Fluorescence was measured
for 6 h at 30(C using a Cytoﬂuor 4000 (Applied Biosystems,
Foster City, CA, USA). This assay is considered to represent
overall MMP activity.
DATA ANALYSES
From the material obtained from each patient, one control
culture and at least one experimental culture were per-
formed. The Ct values of each control and experimental
condition were normalized to GAPDH. Hereafter, each ex-
perimental condition was expressed relative to the corre-
sponding control condition of the same patient, according
to the 2DDCt method. The resulting number of this calcula-
tion indicates whether there is an up- or down-regulation of
gene expression in an experimental condition compared to
its paired untreated control. Now for each subset of exper-
imental conditions (e.g., GlcN-HCl 5 mM, GlcN-S 0.5 mM),
the median of these numbers was calculated. For graphical
display purposes, only the 2DDCt values were expressed
as a 10LOG. Because of the sampling size we used boxe
whisker plots, with the box representing the middle two
quartiles (25e75) and the whiskers the highest and lowest
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Primer and probe nucleotide sequences of the tested genes
Accession no. Primer Probe
COL2 NM_033150 Fw: GGCAATAGCAGGTTCACGTACA CCGGTATGTTTCGTGCAGCCATCCT
Rv: CGATAACAGTCTTGCCCCACTT
AGC1 NM_001135 Fw: TCGAGGACAGCGAGGCC ATGGAACACGATGCCTTTCACCACGA
Rv: TCGAGGGTGTAGCGTGTAGAGA
MMP1 NM_002421 Fw: CTCAATTTCACTTCTGTTTTCTG CACAACTGCCAAATGGGCTTGAAGC
Rv: CATCTCTGTCGGCAAATTCGT
MMP2 NM_004530 Fw: TCAAGTTCCCCGGCGAT TCGCCCCCAAAACGGACAAAGA
Rv: TGTTCAGGTATTGCACTGCCA
MMP3 NM_002422 Fw: TTTTGGCCATCTCTTCCTTCA AACTTCATATGCGGCATCCACGCC
Rv: TGTGGATGCCTCTTGGGTATC
MMP9 NM_004994 Fw: TGAGAACCAATCTCACCGACAG CAGCTGGCAGAGGAATACCTGTACCGC
Rv: TGCCACCCGAGTGTAACCAT
MMP13 NM_002427 Fw: AAGGAGCATGGCGACTTCT CCCTCTGGCCTGCGGCTCA
Rv: TGGCCCAGGAGGAAAAGC
MMP14 NM_004995 Fw: TGCCTGCGTCCATCAACACT AAGACGAATTTGCCATCCTTCCTCTCGT
Rv: CATCAAACACCCAATGCTTGTC
TIMP1 NM_003254 Fw: TGCCGCATCGCCGAGAT CCAGCGCCCAGAGAGAC
Rv: ATGGTGGGTTCTCTGGTG
TIMP2 NM_003255 Fw: ATGGTGGGTTCTCTGGTG CCTGCATCAAGAGAAGTGAC
Rv: CGGTACCACGCACAGGA
TIMP3 NM_000362 Fw: AGGACACATTTTGCCCGATG CCACCCCCAGGACGCCTTCTG
Rv: TGCACATGCTCGCCCA
ADAMTS1 NM_006988 Fw: GGACAGGTGCAAGCTCATCTG CAAGCCAAAGGCATTGGCTACTTCTTCG
Rv: TCTACAACCTTGGGCTGCAAA
ADAMTS4 NM_005099 Fw: CAAGGTCCCATGTGCAACGT CCGAAGAGCCAAGCGCTTTGCTTC
Rv: CATCTGCCACCACCAGTGTCT
ADAMTS5 NM_007038 Fw: TGTCCTGCCAGCGGATGT TTCTCCAAAGGTGACCGATGGCACTG
Rv: ACGGAATTACTGTACGGCCTACA
Fw: forward; Rv: reverse.values, with exclusion in case of outlier variables. Total
MMP activity was calculated as relative ﬂuorescence units
per second and presented as mean and standard deviation
relative to the untreated control, which was set at 100%.
For statistical analysis, a Friedman test with post hocWil-
coxon signed ranks test was performed on the normalized
Ct values (gene expression) and the relative ﬂuorescence
units per second (total MMP activity) using SPSS 11.0.1
(SPSS Inc., Chicago, IL). A P-value 0.05 was considered
to indicate statistically signiﬁcant differences.
Results
ANABOLIC ACTIVITIES
Collagen type II expression (Fig. 1) was down-regulated
by addition of 5 mM GlcN-HCl (7.75-fold; P¼ 0.005,
N¼ 10) and by 5 mM GlcN-S (22.17-fold; P¼ 0.005,
N¼ 10). Aggrecan gene expression (Fig. 2) decreased
2.65-fold by addition of 5 mM GlcN-HCl (P¼ 0.012, N¼ 8)
and 7.73-fold by 5 mM GlcN-S (P¼ 0.008, N¼ 9). Gene ex-
pression was not signiﬁcantly altered by addition of 0.5 mM
GlcN-HCl or 0.5 mM GlcN-S, but showed a trend similar to
that observed with the 5 mM concentration. No effect of ad-
dition of 5 mM Gluc was found.
CATABOLIC ACTIVITIES
ADAMTS1 [Fig. 3(A)] showed no signiﬁcant alteration
in gene expression for both GlcN derivatives (N¼ 10).Aggrecanase-1 (ADAMTS4) [Fig. 3(B)] was down-regulated
6.38-fold by 5 mM GlcN-HCl (P¼ 0.005, N¼ 10) and 7.83-
fold by 5 mM GlcN-S (P¼ 0.005, N¼ 10). Aggrecanase-2
(ADAMTS5) [Fig. 3(C)] revealed a signiﬁcant down-regula-
tion only upon addition of 5 mM GlcN-S (median 4.51-fold;
P¼ 0.005, N¼ 10).
GlcN had no statistically signiﬁcant effect on the expres-
sion of the majority of the MMP genes that were tested (i.e.,
MMP1, 2, 9, 13 and 14). MMP3 (Fig. 4) was the only MMP
that showed a signiﬁcant down-regulation of gene expres-
sion in response to both 5 mM GlcN-HCl (2.02-fold;
P¼ 0.005, N¼ 10) and 5 mM GlcN-S (2.66-fold;
P¼ 0.005, N¼ 10).
The MMP activity assay (Fig. 5) showed an activity for
5 mM GlcN-HCl of 79.5 15.6% (meanSD, N¼ 10) and
91.1 17.1% (mean SD, N¼ 10) for 5 mM GlcN-S, as
compared to the total MMP activity of the untreated control
which was set at 100%. This reduction in total MMP activity
was only statistically signiﬁcant for GlcN-HCl (P¼ 0.047).
For both 0.5 mM concentrations of the GlcN derivatives,
total MMP activity was not reduced as compared to the
untreated control.
In order to obtain a broad view of the catabolic potential,
expression of the natural tissue inhibitors of MMPs (TIMPs)
was also studied. The gene expression of the TIMPs
(Fig. 6) was only slightly down-regulated by the addition
of 5 mM GlcN-HCl and 5 mM GlcN-S. The only statistically
signiﬁcant alteration was a 3.07-fold down-regulation of
TIMP3 gene expression after addition of 5 mM GlcN-S
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addition of 0.5 mM GlcN-HCl or 0.5 mM GlcN-S, but
showed a trend similar to that observed with the 5 mM con-
centration. No effect of addition of 5 mM Gluc was found.
Catabolic gene expression was not substantially inﬂu-
enced by 5 mM Gluc, with the exception of a 1.54-fold
up-regulation of the MMP14 gene expression compared to
control (P¼ 0.021, N¼ 9).
GLcN-HCl vs GlcN-S
To explain some of the literature differences regarding
the in vitro effects of GlcN, we also tested if there was a dif-
ference in alteration of gene expression between treatment
with 5 mM GlcN-HCl and 5 mM GlcN-S. We found that ex-
pression of ADAMTS5 (P¼ 0.008, N¼ 9), TIMP3
(P¼ 0.008, N¼ 9) and aggrecan (P¼ 0.012, N¼ 8) was
signiﬁcantly more down-regulated by 5 mM GlcN-S than
by 5 mM GlcN-HCl.
Discussion
Addition of GlcN derivatives (both the sulphate and the
hydrochloride salt) at a concentration of 5 mM to osteoar-
thritic cartilage in vitro leads to a down-regulation of genes
that encode for anabolic (e.g., COL2 and aggrecan) and
catabolic (ADAMTS enzymes and MMPs) processes. For
the MMPs, this was also shown at protein activity level.
From all published studies that found an inhibition of
proteoglycan production by the addition of GlcN, four
were performed using a cartilage explant model12,14,17,19.
Two of these studies used equine cartilage and the other
two used bovine cartilage. In all these studies, IL-1,
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Fig. 1. Change in collagen type II gene expression in human oste-
oarthritic cartilage after culture with GlcN. Cartilage explants were
pre-cultured for 3 days, followed by 4 days of treatment with
5 mM GlcN-HCl (N¼ 10), 5 mM GlcN-S (N¼ 10) or 5 mM Gluc
(N¼ 9). The n-fold change normalized to GAPDH and relative to
the untreated control (indicated by the dotted line) is displayed on
the vertical axis. Negative values indicate down-regulation and pos-
itive values indicate up-regulation of gene expression. *Indicates
a P-value 0.05.lipopolysaccharide or retinoic acid was used to induce a cat-
abolic response and mimic OA. The GlcN concentrations
that signiﬁcantly reduced proteoglycan production varied
from 5 mM to 116 mM. Lower GlcN concentrations used
in these studies did not lead to a signiﬁcant decrease of pro-
teoglycan production. This is in agreement with our ﬁnding
that 5 mM concentrations of both GlcN derivatives led to
a signiﬁcant down-regulation of aggrecan gene expression,
while the 0.5 mM concentrations did not. Although it was not
a subject of our investigation, it might be expected that
a down-regulation of aggrecan gene expression as we
have found ultimately will lead to less GAG production.
Two earlier studies using human cell clusters found no ef-
fect on COL2 production after addition of crystalline GlcN-S
(Dona) at concentrations up to 0.56 mM5,7. In our data we
could not ﬁnd a signiﬁcant effect for this concentration as
well. In contrast, for the 5 mM concentration we found a sig-
niﬁcant down-regulation of COL2 gene expression. In oste-
oarthritic cartilage, expression of MMPs, especially, MMP1,
2, 3, 9, 13 and 14, has been demonstrated32. In the present
study we show that addition of GlcN to culture medium in-
hibits MMP activity. In the assay we used, only active
MMPs were measured. While pro-MMP levels only provide
information on the potential of the system to breakdown ma-
trix, active MMPs are the molecular forms of the enzyme
that causes the actual tissue breakdown. On gene expres-
sion level, only MMP3 (stromelysin-1) was signiﬁcantly
down-regulated. At this point we do not have an explanation
for this. We can speculate that it probably has to do with dif-
ferences in regulation of gene expression of the different
MMPs. In our view, this apparent rather selective inhibition
of MMP3 may even be an advantage. If GlcN would down-
regulate all MMPs (as if it were a broad-spectrum MMP in-
hibitor) normal tissue turnover in other connective tissues
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Fig. 2. Change in aggrecan gene expression in human osteoarthritic
cartilage after culture with GlcN. Cartilage explants were pre-
cultured for 3 days, followed by 4 days of treatment with 5 mM
GlcN-HCl (N ¼ 8), 5 mM GlcN-S (N ¼ 9) or 5 mM Gluc (N ¼ 7).
The n-fold change normalized toGAPDH and relative to the untreated
control (indicated by the dotted line) is shown on the vertical axis.
Negative values indicate down-regulation and positive values indi-
cate up-regulation of gene expression. *Indicates a P-value 0.05.
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Fig. 3. Change in aggrecanase gene expression in human osteoarthritic cartilage after culture with GlcN. Cartilage explants were pre-cultured
for 3 days, followed by 4 days of treatment with 5 mM GlcN-HCl (N¼ 10), 5 mM GlcN-S (N¼ 10) or 5 mM Gluc (N¼ 9). The n-fold change for
ADAMTS1 (panel A), ADAMTS4 (panel B) and ADAMTS5 (panel C) normalized to GAPDH and relative to the untreated control (indicated by
the dotted line) is displayed on the vertical axis. Negative values indicate down-regulation and positive values indicate up-regulation of gene
expression. *Indicates a P-value 0.05.than cartilage may also be suppressed, causing unwanted
side effects. The apparent selective MMP3 inhibition may
block the excess proteolytic activity that is inherent to the
OA disease state, due to its pivotal role in the MMP activa-
tion cascade33, but may leave normal tissue turnover unaf-
fected. We have found that addition of 5 mM GlcN-HCl or
5 mM GlcN-S leads to a signiﬁcant down-regulation, when
compared to the untreated control. This signiﬁcant down-
regulation is in accordance with the ﬁndings by Gouze
et al.16, who used rat chondrocytes in monolayer culture
stimulated with IL-1b to mimic OA. The addition of GlcN in
the same concentration as Gluc to the culture medium,
led to signiﬁcant lower MMP3 mRNA levels. In contrast, an-
other study using human osteoarthritic cells in cell suspen-
sion culture, showed no effect on MMP3 mRNA levels with
GlcN-S concentration up to 0.2 mM6. The latter being in
agreement with our study, as we could not ﬁnd a signiﬁcant
effect of the 0.5 mM concentrations on MMP3 gene expres-
sion either. Lower MMP activity in the culture medium as we
observed upon the addition of 5 mM GlcN was also de-
scribed in two studies in which GlcN was added to lipopoly-
saccharide treated equine chondrocytes17,22. Thus, our
results suggest that addition of GlcN in vitro leads to less
MMP-mediated extra-cellular matrix degradation.
Next to MMP3, our results showed that ADAMTS4 ex-
pression is down-regulated by GlcN-HCl and GlcN-S and
that ADAMTS5 expression is signiﬁcantly down-regulated
by 5 mM GlcN-S. This conﬁrms the results of Sandy
et al.11 who found less aggrecanase activity in a rat chon-
drosarcoma cell line and bovine explants after addition of
GlcN in a dose-dependent manner. This down-regulation
of ADAMTS4 and ADAMTS5 by addition of GlcN might
lead to preservation of the extra-cellular matrix, since these
two aggrecanases are signiﬁcantly up-regulated in OA,
when compared to normal cartilage34. Addition of GlcN
had no effect on expression of ADAMTS1, which was
also identiﬁed as an aggrecanase35. Since up-regulation
of ADAMTS1 expression has not been reported in OA, its
aggrecan-degrading activity seems of less importance36.
To obtain a broad view on MMP activation, the expres-
sion of TIMPs was studied. TIMP1, 2 and 3 are important
regulators of the proteolytic activity of MMPs by endoge-
nous inhibition37. Addition of GlcN did not affect the expres-
sion of TIMP1 and TIMP2. Apart from inhibitory effects onMMPs, TIMP3 was also shown to be a potent endogenous
inhibitor of aggrecanases and therefore protects against ag-
grecanase-mediated cartilage degeneration38e40. Since
TIMP3 was signiﬁcantly down-regulated by 5 mM GlcN-S,
aggrecanase activity might be less inhibited as expected
purely based on the down-regulation of ADAMTS4 and
ADAMTS5 gene expression upon adding 5 mM GlcN-S
in vitro.
To evaluate cell death related effects, due to toxicity of
the used GlcN concentration in our study, we compared
the total amount of RNA per milligram wet weight of the
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Fig. 4. Change in MMP3 gene expression in human osteoarthritic
cartilage after culture with GlcN. Cartilage explants were pre-
cultured for 3 days, followed by 4 days of treatment with 5 mM
GlcN-HCl (N¼ 10), 5 mM GlcN-S (N¼ 10) or 5 mM Gluc (N¼ 9).
The n-fold change normalized to GAPDH and relative to the
untreated control (indicated by the dotted line) is shown on the ver-
tical axis. Negative values indicate down-regulation and positive
values indicate up-regulation of gene expression. *Indicates a
P-value 0.05.
255Osteoarthritis and Cartilage Vol. 14, No. 3original tissue at the end of the culture period between con-
trol group and 5 mM GlcN treated conditions. No statistically
signiﬁcant difference was found. Furthermore, we found no
signiﬁcant difference in GAPDH expression between control
group and all tested 5 mM concentrations. We thus believe
that the effects we have found on gene expression are not
based on cell death, but on actual regulatory effects of
GlcN. Detrimental effects of high dose GlcN-HCl on bovine
cartilage explants have been reported, but only with con-
centrations above 10 mM, which were twice as high as
was used in this study12. The same group did not observe
any effects on cell viability after 24 h culture with less than
10 mM GlcN-HCl.
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Fig. 5. Total MMP activity in the culture medium of human osteoar-
thritic cartilage explants after 3 days pre-culture, followed by 4 days
of treatment with 5 mM GlcN-HCl (N¼ 10), 5 mM GlcN-S (N¼ 10)
or 5 mM Gluc (N¼ 9). Total MMP activity is displayed as a percent-
age relative to the MMP activity in medium of the untreated control,
which was set at 100% (indicated by the dotted line). *Indicates a
P-value 0.05.In osteoarthritic knee-joint effusions, the mean Gluc con-
centration was previously shown to be 5.4 mM, with a range
comparable to the reference range for serum41. With this in
mind we decided to use medium with low glucose concen-
tration (5.55 mM), since this comes closest to the physiolog-
ical situation. In the experimental conditions, GlcN was
added at concentrations equimolar with or 10 times lower
than glucose concentration in medium. In vitro, exogenous
GlcN was shown to be incorporated in newly formed chon-
droitin sulphate in cultured mouse chondrocytes and immor-
talized human chondrocytes when added at an equimolar
concentration with Gluc in the culture medium10,42. When
Gluc concentration became higher than the GlcN concen-
tration, cells utilized less exogenous GlcN for the formation
of chondroitin sulphate, but preferably incorporated GlcN
that was endogenously formed from Gluc. These results
suggest that not only the absolute concentration of GlcN
but also the GlcN-to-Gluc ratio plays an important role in
the utilization and therefore effectiveness of exogenously
provided GlcN. This might explain why we did not ﬁnd any
signiﬁcant results of the addition of 0.5 mM GlcN in culture
medium with a 10 times higher glucose concentration.
When trying to translate our in vitro results to clinical
in vivo applicability of GlcN, the intra-articular GlcN concen-
tration that can be reached after administration of this food
additive to the patient is of concern. Since the ﬁrst studies
were performed on the effect of GlcN on articular cartilage
there has been debate on this topic. When GlcN-HCl is ad-
ministered to horses in a single dose, intravenously as well
as orally, in a dosage per kilogram bodyweight at clinically
relevant levels, GlcN concentrations in the synovial ﬂuid
ranged from 9 mM to 15 mM and from 0.3 mM to 0.7 mM, re-
spectively43. Although these concentrations were less than
10% of the obtained serum concentrations at the same
time, GlcN was still detectable in synovial ﬂuids 6 h after it
was nearly completely cleared from the serum. Several
studies with radioactive labelled GlcN administered to ani-
mals have shown that articular cartilage has the capacity
to accumulate and retain GlcN44e46. This is conﬁrmed in
a study with six healthy male volunteers who received a
single dose 14C labelled GlcN-S orally, intravenously or
intramuscularly47. These studies indicate that due to its*
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Fig. 6. Change in TIMP gene expression in human osteoarthritic cartilage after culture with GlcN. Cartilage explants were pre-cultured for 3
days, followed by 4 days of treatment with 5 mM GlcN-HCl, 5 mM GlcN-S or 5 mM Gluc. The n-fold change for TIMP1 (panel A: GlcN-HCl,
N¼ 10; GlcN-S, N¼ 10; Gluc, N¼ 9), TIMP2 (panel B: GlcN-HCl, N¼ 9; GlcN-S, N¼ 9; Gluc, N¼ 8) and TIMP3 (panel C: GlcN-HCl,
N¼ 10; GlcN-S, N¼ 10; Gluc, N¼ 9) normalized to GAPDH and relative to the untreated control (indicated by the dotted line) is shown on
the vertical axis. Negative values indicate down-regulation and positive values indicate up-regulation of gene expression. *Indicates a
P-value 0.05. Missing whiskers in a graph are due to the exclusion of outliers, which results in the 25th and 75th percentile becoming
the lowest value and the highest value, respectively.
256 E. J. Uitterlinden et al.: Glucosamine effects on human cartilagespecial capacity to accumulate and retain GlcN, the
concentrations of GlcN within the articular cartilage can ac-
tually be much higher than those found in the surrounding
synovial ﬂuid. It might however still be questioned whether
5 mM levels will ever reach the joint. In contrast with the
previously mentioned synovial glucose concentration of
5 mM, Windhaber et al.48 mentioned, based on measure-
ments with microelectrodes, a Gluc concentration of 1 mM
directly surrounding the chondrocytes. With the possible im-
portance of the GlcN-to-Gluc ratio in mind, GlcN concentra-
tion perhaps does not have to be as high as 5 mM in order
to make exogenous GlcN effective in vivo.
In conclusion, our results suggest that enzymatic break-
down of the extra-cellular matrix in vitro might be reduced
by the addition of GlcN. This was suggested by down-regu-
lation of transcript abundances and reducedMMP enzymatic
activity, which preserves the cartilage matrix in the catabolic
OA situation. On the other hand, on transcription level we
showed that treatment with 5 mM GlcN-HCl or 5 mM GlcN-S
led to a signiﬁcant down-regulation of collagen type II and
aggrecan expression. Whether this down-regulation of
gene expression also results in less extra-cellular matrix pro-
duction was not investigated in this study. However, restora-
tion of already damaged cartilage is not to be expected.
Taking this into consideration, our results indicate that chon-
droprotective properties of GlcN may be based on inhibiting
further degradation due to catabolic activities, rather than on
the ability to rebuild cartilage.
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